Necitumumab
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly.It binds to the epidermal growth factor receptor (EGFR).[4] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[5][6][3] It was counterproductive in non-squamous non-small-cell lung carcinoma.You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.